Cells (Aug 2023)

Development of Beta-Amyloid-Specific CAR-Tregs for the Treatment of Alzheimer’s Disease

  • Valerie Saetzler,
  • Tobias Riet,
  • Andrea Schienke,
  • Pierre Henschel,
  • Kiara Freitag,
  • Alexander Haake,
  • Frank L. Heppner,
  • Laura Elisa Buitrago-Molina,
  • Fatih Noyan,
  • Elmar Jaeckel,
  • Matthias Hardtke-Wolenski

DOI
https://doi.org/10.3390/cells12162115
Journal volume & issue
Vol. 12, no. 16
p. 2115

Abstract

Read online

Background: Alzheimer’s disease (AD) is a neurodegenerative disease that remains uncured. Its pathogenesis is characterized by the formation of β-amyloid (Aβ) plaques. The use of antigen-specific regulatory T cells (Tregs) through adoptive transfer has shown promise for the treatment of many inflammatory diseases, although the effectiveness of polyspecific Tregs is limited. Obtaining a sufficient number of antigen-specific Tregs from patients remains challenging. Aims and Methods: To address this problem, we used an antibody-like single-chain variable fragment from a phage library and subsequently generated a chimeric antigen receptor (CAR) targeting β-amyloid. Results: The β-amyloid-specific CARs obtained were stimulated by both recombinant and membrane-bound Aβ isolated from the murine brain. The generated CAR-Tregs showed a normal Treg phenotype, were antigen-specific activatable, and had suppressive capacity. Conclusion: This study highlights the potential of CAR technology to generate antigen-specific Tregs and presents novel approaches for developing functional CARs.

Keywords